Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ASPIRIN THERAPY IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY
Autore:
BECK RW; HAYREH SS; PODHAJSKY PA; TAN ES; MOKE PS;
Indirizzi:
JAEB CTR HLTH RES,3010 E 138TH AVE,STE 9 TAMPA FL 33613 UNIV IOWA,DEPT OPHTHALMOL IOWA CITY IA 52242
Titolo Testata:
American journal of ophthalmology
fascicolo: 2, volume: 123, anno: 1997,
pagine: 212 - 217
SICI:
0002-9394(1997)123:2<212:ATINAI>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLINICAL PROFILE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
6
Recensione:
Indirizzi per estratti:
Citazione:
R.W. Beck et al., "ASPIRIN THERAPY IN NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY", American journal of ophthalmology, 123(2), 1997, pp. 212-217

Abstract

PURPOSE: To determine the benefit of aspirin in reducing the risk of nonarteritic anterior ischemic optic neuropathy in the fellow eye following its occurrence in the first eye. METHODS: A retrospective cohortstudy was conducted on 431 patients, 153 of whom were and 278 of whomwere not prescribed aspirin following the development of unilateral nonarteritic anterior ischemic optic neuropathy. RESULTS: The 2-year cumulative probability of nonarteritic anterior ischemic optic neuropathy in the fellow eye was 7% in the aspirin group and 15% in the no-aspirin group, and 5-year cumulative probabilities were 17% and 20%, respectively. Compared with the no-aspirin group, the rate ratio for nonarteritic anterior ischemic optic neuropathy in the fellow eye in the aspirin-user group was 0.43 (95% confidence interval, 0.19 to 0.92) over the first 2 years and 0.68 (95% confidence interval, 0.36 to 1.26) over the 5-year period. The overall calculated 5-year risk was 19%; however, if none of the patients with incomplete follow-up developed nonarteritic anterior ischemic optic neuropathy in the fellow eye, then the 5-year risk would be about 12%. CONCLUSIONS: The 5-year risk of nonarteritic anterior ischemic optic neuropathy occurring in the second eye is far lower than that reported by previous studies. Our results suggest a possible short-term but little or no long-term benefit to aspirinin reducing the risk of nonarteritic anterior ischemic optic neuropathy in the fellow eye. However, this finding must be viewed with caution because this study was not conducted prospectively with a controlledprotocol.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 03:16:35